{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK1349572+%28dolutegravir%29&page=5", "query": { "intervention": "GSK1349572 (dolutegravir)", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 147, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK1349572+%28dolutegravir%29&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK1349572+%28dolutegravir%29&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T16:33:28.581Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03110380", "title": "Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" }, { "name": "DTG Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" }, { "name": "B/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 567, "start_date": "2017-06-12", "completion_date": "2021-02-10", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-10-12T16:33:28.581Z", "location_count": 66, "location_summary": "Phoenix, Arizona • Los Angeles, California • Oakland, California + 47 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03110380" }, { "nct_id": "NCT02831764", "title": "An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "Lamivudine (3TC)", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 722, "start_date": "2016-07-18", "completion_date": "2022-06-29", "has_results": true, "last_update_posted_date": "2023-12-07", "last_synced_at": "2026-10-12T16:33:28.581Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Leandro", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02831764" }, { "nct_id": "NCT00867152", "title": "GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Darunavir", "type": "DRUG" }, { "name": "Etravirine", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Lopinavir/ritonavir", "type": "DRUG" }, { "name": "GSK1349572", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 17, "start_date": "2009-04", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2012-02-22", "last_synced_at": "2026-10-12T16:33:28.581Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00867152" }, { "nct_id": "NCT02893488", "title": "Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "DTG/ABC/3TC FDC DISPERSIBLE TABLET", "type": "DRUG" }, { "name": "EPZICOM (ABC/3TC)", "type": "DRUG" }, { "name": "TIVICAY (DTG)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2016-09-01", "completion_date": "2016-11-25", "has_results": false, "last_update_posted_date": "2017-08-04", "last_synced_at": "2026-10-12T16:33:28.581Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02893488" }, { "nct_id": "NCT02064374", "title": "Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "Metformin 500 mg q12h", "type": "DRUG" }, { "name": "Dolutegravir 50 mg q24h", "type": "DRUG" }, { "name": "Dolutegravir 50 mg q12h", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2014-02", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-05-26", "last_synced_at": "2026-10-12T16:33:28.581Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02064374" }, { "nct_id": "NCT02715479", "title": "A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "Dolutegravir", "type": "DRUG" }, { "name": "BMS955176", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 14, "start_date": "2016-04", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2017-01-19", "last_synced_at": "2026-10-12T16:33:28.581Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02715479" }, { "nct_id": "NCT03332095", "title": "Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Doravirine (DOR)", "type": "DRUG" }, { "name": "Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)", "type": "DRUG" }, { "name": "Antiretroviral (ARV) medications", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 55, "start_date": "2018-07-02", "completion_date": "2022-05-25", "has_results": true, "last_update_posted_date": "2023-02-14", "last_synced_at": "2026-10-12T16:33:28.581Z", "location_count": 4, "location_summary": "Aurora, Colorado • Boston, Massachusetts • Memphis, Tennessee + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03332095" }, { "nct_id": "NCT01231529", "title": "GSK1349572 Hepatic Impairment Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects", "Hepatic Impairment", "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "GSK1349572", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 16, "start_date": "2010-11-19", "completion_date": "2011-06-04", "has_results": false, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-10-12T16:33:28.581Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01231529" }, { "nct_id": "NCT07202546", "title": "A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VH4524184", "type": "DRUG" }, { "name": "Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets", "type": "DRUG" }, { "name": "Dolutegravir / Lamivudine (DTG/3TC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2026-02-11", "completion_date": "2028-05-22", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-12T16:33:28.581Z", "location_count": 34, "location_summary": "Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07202546" }, { "nct_id": "NCT01328041", "title": "A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "dolutegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2011-05", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2016-01-07", "last_synced_at": "2026-10-12T16:33:28.581Z", "location_count": 42, "location_summary": "Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 32 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01328041" } ] }